KDR and neoplasm: Tumor angiogenesis is a particular feature in renal cell carcinoma and, over time, numerous anti-angiogenic agents have been approved for this pathology: VEGF/VEGFR pathway inhibitors (tivozanib), multi-kinase inhibitors (sorafenib, pazopanib, sunitinib, axitinib, lenvatinib, cabozantinib), or mTOR inhibitors (temsirolimus, everolimus).